Milvexian
- Generic Name
- Milvexian
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H23Cl2F2N9O2
- CAS Number
- 1802425-99-5
- Unique Ingredient Identifier
- 0W79NDQ608
- Background
Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20000
- Registration Number
- NCT05757869
- Locations
- 🇺🇸
The Queens Medical Center, Honolulu, Hawaii, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Advocate Heart Institute, Oak Lawn, Illinois, United States
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16000
- Registration Number
- NCT05754957
- Locations
- 🇺🇸
Northwest Heart Clinical Research, LLC., Tomball, Texas, United States
🇮🇳Lisie Hospital, Cochin, India
🇮🇳Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India
A Study of Milvexian in Healthy Adult Females
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 20
- Registration Number
- NCT05706753
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT05702034
- Locations
- 🇺🇸
Shady Grove Office, Rockville, Maryland, United States
🇦🇺Box Hill Hospital, Box Hill, Australia
🇨🇦Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 115
- Registration Number
- NCT04844424
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04543383
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 23
- Registration Number
- NCT04388501
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.